Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review

Overview

Journal Crit Care Explor

Specialty Critical Care

Date 2021 Jul 19

PMID 34278319

Citations 5

Authors

Michael Behal

Brooke Barlow

Breanne Mefford

Melissa L Thompson Bastin

J Chris Donaldson

Melanie Laine

Brittany D Bissell

Affiliations

Soon will be listed here.

Abstract

Data Sources: PubMed (inception to March 2021) database search and manual selection of bibliographies from selected articles.

Study Selection And Data Extraction: Articles relevant to coronavirus disease 2019, management of severe acute respiratory syndrome coronavirus 2-associated respiratory failure, and prevalence of secondary infections with pharmacotherapies were selected. The MeSH terms "COVID-19," "secondary infection," "SARS-CoV-2," "tocilizumab," and "corticosteroids" were used for article identification. Articles were narratively synthesized for this review.

Data Synthesis: Current data surrounding the use of tocilizumab and/or corticosteroids for coronavirus disease 2019 management are limited given the short follow-up period and conflicting results between studies. Further complicating the understanding of immune modulator role is the lack of definitive understanding of clinical impact of the immune response in coronavirus disease 2019.

Conclusions: Based on the current available literature, we suggest prolonged trials and follow-up intervals for those patients managed with immune modulating agents for the management of coronavirus disease 2019.

Citing Articles

Risk Factors Associated with the Development of Hospital-Acquired Infections in Hospitalized Patients with Severe COVID-19.

Solis-Huerta F, Martinez-Guerra B, Roman-Montes C, Tamez-Torres K, Rajme-Lopez S, Ortiz-Conchi N Antibiotics (Basel). 2023; 12(7).

PMID: 37508204 PMC: 10376785. DOI: 10.3390/antibiotics12071108.

Viral reactivations and co-infections in COVID-19 patients: a systematic review.

Kim J, Ragusa M, Tortosa F, Torres A, Gresh L, Mendez-Rico J BMC Infect Dis. 2023; 23(1):259.

PMID: 37101275 PMC: 10131452. DOI: 10.1186/s12879-023-08117-y.

A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection.

Leonso A, Brown K, Prol R, Rawat S, Khunger A, Bromberg R Infect Dis Rep. 2022; 14(3):446-452.

PMID: 35735758 PMC: 9222568. DOI: 10.3390/idr14030048.

Intracranial complications of hypercoagulability and superinfection in the setting of COVID-19: illustrative cases.

Blitz S, McMahon J, Chalif J, Jarvis C, Segar D, Northam W J Neurosurg Case Lessons. 2022; 3(21):CASE22127.

PMID: 35734230 PMC: 9204919. DOI: 10.3171/CASE22127.

A Unique Triad of Invasive Sinusitis, Brain Abscess with Focal Cerebritis, and COVID-19.

Shahab A, Arora A, Chhina S, Dhillon S, Nazir U Am J Case Rep. 2021; 22:e933177.

PMID: 34702794 PMC: 8557857. DOI: 10.12659/AJCR.933177.

References

Cervantes-Barragan L, Kalinke U, Zust R, Konig M, Reizis B, Lopez-Macias C . Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 2009; 182(2):1099-106. DOI: 10.4049/jimmunol.182.2.1099. View

Hermine O, Mariette X, Tharaux P, Resche-Rigon M, Porcher R, Ravaud P . Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(1):32-40. PMC: 7577198. DOI: 10.1001/jamainternmed.2020.6820. View

Razazi K, Arrestier R, Haudebourg A, Benelli B, Carteaux G, Decousser J . Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease. Crit Care. 2020; 24(1):699. PMC: 7747772. DOI: 10.1186/s13054-020-03417-0. View

Campochiaro C, Della-Torre E, Cavalli G, Luca G, Ripa M, Boffini N . Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020; 76:43-49. PMC: 7242960. DOI: 10.1016/j.ejim.2020.05.021. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T . Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2013; 41(1):15-23. DOI: 10.3899/jrheum.130466. View

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Arastehfar A, Carvalho A, van de Veerdonk F, Jenks J, Koehler P, Krause R . COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment. J Fungi (Basel). 2020; 6(2). PMC: 7346000. DOI: 10.3390/jof6020091. View

10.

Chiu Y, Chen D . Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2019; 16(2):207-228. DOI: 10.1080/1744666X.2019.1705785. View

11.

Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View

12.

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F . Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; 19(7):102568. PMC: 7252115. DOI: 10.1016/j.autrev.2020.102568. View

13.

Waljee A, Rogers M, Lin P, Singal A, Stein J, Marks R . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017; 357:j1415. PMC: 6284230. DOI: 10.1136/bmj.j1415. View

14.

Alattar R, Ibrahim T, Shaar S, Abdalla S, Shukri K, Daghfal J . Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020; 92(10):2042-2049. PMC: 7267594. DOI: 10.1002/jmv.25964. View

15.

Giacobbe D, Battaglini D, Ball L, Brunetti I, Bruzzone B, Codda G . Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest. 2020; 50(10):e13319. PMC: 7323143. DOI: 10.1111/eci.13319. View

16.

Schiff M, Kremer J, Jahreis A, Vernon E, Isaacs J, van Vollenhoven R . Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011; 13(5):R141. PMC: 3308069. DOI: 10.1186/ar3455. View

17.

Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R . Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. J Infect. 2020; 81(4):e11-e17. PMC: 7345400. DOI: 10.1016/j.jinf.2020.07.008. View

18.

Lokugamage K, Hage A, de Vries M, Valero-Jimenez A, Schindewolf C, Dittmann M . Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV. J Virol. 2020; 94(23). PMC: 7654262. DOI: 10.1128/JVI.01410-20. View

19.

Zhao L, Jha B, Wu A, Elliott R, Ziebuhr J, Gorbalenya A . Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe. 2012; 11(6):607-16. PMC: 3377938. DOI: 10.1016/j.chom.2012.04.011. View

20.

Salvarani C, Dolci G, Massari M, Merlo D, Cavuto S, Savoldi L . Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(1):24-31. PMC: 7577199. DOI: 10.1001/jamainternmed.2020.6615. View